NEK7 and metabolic syndrome: If NEK7 inhibitors without effects on kinase activity could be developed, such compounds could be valuable candidates against gout or other diseases characterized by the inflammasome such as cardiovascular diseases, metabolic syndrome, and neurodegenerative disorders.